← Back
Data updated: Mar 10, 2026
ZAMEER PHARMS
OncologyInfectious DiseaseDermatology
ZAMEER PHARMS is a generic drug manufacturer focused on Oncology, Infectious Disease, Dermatology.
2021
Since
3
Drugs
-
Trials
36
Approved (2yr)
Key Drugs
No active drugs
Recent Activity
CHLORPROMAZINE HYDROCHLORIDE 2026-01-26
FLUPHENAZINE HYDROCHLORIDE 2025-11-18
CHLORPROMAZINE HYDROCHLORIDE 2025-10-10
CHLORPROMAZINE HYDROCHLORIDE 2025-04-25
TROSPIUM CHLORIDE 2025-04-04
Labeling
FLUPHENAZINE HYDROCHLORIDE 2025-02-26
Labeling
FLUPHENAZINE HYDROCHLORIDE 2025-01-24
Labeling
FLUPHENAZINE HYDROCHLORIDE 2025-01-22
Labeling
FLUPHENAZINE HYDROCHLORIDE 2025-01-22
Labeling
FLUPHENAZINE HYDROCHLORIDE 2025-01-22
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 52%
0 drugs Phase 3: 3 Phase 1: 2
Infectious Disease 30%
0 drugs Phase 3: 1 Phase 2: 2
Dermatology 19%
0 drugs Phase 3: 1 Phase 1: 1
Pipeline Strength Pro
Loading...
Competitors Pro
Pfizer big-pharma
Oncology, Infectious Disease, Dermatology
Baxter specialty
Infectious Disease, Oncology, Dermatology
COSETTE other
Dermatology, Infectious Disease, Oncology
KING PHARMS LLC big-pharma
Infectious Disease, Dermatology, Oncology
FOUGERA PHARMS other
Dermatology, Infectious Disease, Oncology
Active (1)
Discontinued (2)
Company Info
- First Approval
- 2021-10-20
- Latest
- 2025-01-22
- Applications
- 3